Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Chronic Urticaria - What Marcus Taught Us and Where We Are
Description
The discussion focuses on the significant contributions of Marcus to the field of chronic urticaria (hives), emphasizing his impact on understanding its pathophysiology and treatment. The speaker acknowledges that while others, like Malcolm Green and Clive Gratton, have also contributed, Marcus was crucial in improving the lives of patients suffering from urticaria. They explore the evolving understanding of the disease, emphasizing the importance of identifying co-factors and autoimmune responses in patients. Marcus's development of an effective clinic for chronic spontaneous urticaria (CSU) and his pivotal role in the advancement of treatment methods, including the introduction of omalizumab, are highlighted. The talk also touches on Marcus's efforts in connecting the global urticaria community, showcasing his work in establishing guidelines, supporting research, and creating the U Care network. His enthusiasm for social media and technology is illustrated by his involvement in creating an app for patient education. Overall, the speaker credits Marcus with fostering collaboration and driving progress in urticaria research, treatment, and patient management, ultimately changing the landscape of care for many.
View moreConclusions
- Marcus Maurer significantly advanced the understanding of chronic spontaneous urticaria (CSU) pathophysiology, revealing the relevance of autoantibodies like IgE anti-TPO.
- The majority of CSU patients historically lacked effective treatment options, as they were often dismissed by dermatologists.
- The identification of non-allergenic factors contributing to CSU, including infections and stress, led to more targeted research and treatment approaches.
- Omalizumab was established as an effective treatment for CSU, particularly benefiting those with elevated IgE autoantibodies.
- Research under Marcus's guidance facilitated the development of new therapies, such as Bruton's Tyrosine Kinase Inhibitors (BTKis) and monoclonal antibodies, indicating a promising future in CSU management.
- Marcus played a crucial role in connecting the global urticaria community, establishing collaborative research networks and patient support systems.
- The ongoing studies of new biologic therapies imply that future treatments for CSU may provide even better outcomes than current options.
- Altrichter et al ., PLoS One. 2011;6:e14794
- Maurer et al ., J Allergy Clin Immunol 2011;128:202.e5-
- Maurer et al ., N Engl J Med. 2013;368:924-35
- Kolkhir et al ., Nat Rev Dis Primers. 2022;8:61
- Zuberbier et al ., Allergy.
- Maurer et al ., J Allergy Clin Immunol 2022;150:1498-1506
- Metz et al ., N Engl J Med ., March 6th 2025
- Terhorst-Molawi et al ., Allergy 2023; 78:1269-1279
- Maurer and Metz et al ., EADV 2024, oral late breaker